ATE106016T1 - Verfahren und mittel zur erleichterung der schmerzen maligner tumore. - Google Patents

Verfahren und mittel zur erleichterung der schmerzen maligner tumore.

Info

Publication number
ATE106016T1
ATE106016T1 AT87900479T AT87900479T ATE106016T1 AT E106016 T1 ATE106016 T1 AT E106016T1 AT 87900479 T AT87900479 T AT 87900479T AT 87900479 T AT87900479 T AT 87900479T AT E106016 T1 ATE106016 T1 AT E106016T1
Authority
AT
Austria
Prior art keywords
methods
malignant tumors
deficiency syndrome
immune deficiency
acquired immune
Prior art date
Application number
AT87900479T
Other languages
English (en)
Inventor
John Mcmichael
Original Assignee
John Mcmichael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Mcmichael filed Critical John Mcmichael
Application granted granted Critical
Publication of ATE106016T1 publication Critical patent/ATE106016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Optical Integrated Circuits (AREA)
  • Waveguides (AREA)
  • Waveguide Aerials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT87900479T 1985-12-09 1986-12-05 Verfahren und mittel zur erleichterung der schmerzen maligner tumore. ATE106016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/806,626 US4689222A (en) 1985-01-18 1985-12-09 Methods and materials for alleviation of pain symptoms of malignant neoplasia

Publications (1)

Publication Number Publication Date
ATE106016T1 true ATE106016T1 (de) 1994-06-15

Family

ID=25194466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87900479T ATE106016T1 (de) 1985-12-09 1986-12-05 Verfahren und mittel zur erleichterung der schmerzen maligner tumore.

Country Status (5)

Country Link
US (1) US4689222A (de)
EP (1) EP0249629B1 (de)
JP (1) JPH07112981B2 (de)
AT (1) ATE106016T1 (de)
WO (1) WO1987003487A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851395A (en) * 1976-07-07 1989-07-25 Kureha Kagaku Kogyo Kabushiki Kausha Nitrogen-containing polysaccharide
US4883662A (en) * 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US4970071A (en) * 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
JPH08188539A (ja) * 1985-01-18 1996-07-23 John Mcmichael 悪性腫瘍に伴う疼痛症状を緩和する方法
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US4966753A (en) * 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
DE69019956T2 (de) * 1989-10-06 1995-11-23 Janos Szabo Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen, insbesondere pyogener und atopischer dermatitis und verfahren zu deren herstellung.
GB9010058D0 (en) * 1990-05-04 1990-06-27 Health Lab Service Board Method and composition for the treatment of cancer
CA2127107C (en) * 1991-12-31 2007-06-19 Bruce L. A. Carter Methods and compositions for reducing blood loss
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US5877198A (en) * 1996-10-17 1999-03-02 Milkhaus Laboratory, Inc. Treatment of urinary incontinence
US6156780A (en) * 1996-10-17 2000-12-05 Milkhaus Laboratory, Inc. Treatment of fecal incontinence
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
ATE482695T1 (de) * 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP2219622A1 (de) 2007-12-06 2010-08-25 Durect Corporation Verfahren zur behandlung von schmerzen, arthritischen zuständen oder entzündung im zusammenhang mit einer chronischen erkrankung
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
WO2014063071A1 (en) 2012-10-18 2014-04-24 Neuralight Hd, Llc Treatment of depression and ptsd
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2310937A (en) * 1935-05-02 1943-02-16 Canadian American Pharmaceutic Pain-alleviating material
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
FR6513M (de) * 1967-07-12 1968-12-02
US3855197A (en) * 1969-05-20 1974-12-17 Cassenne Lab Sa Glycoproteins extracted from microorganisms
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4002738A (en) 1975-05-30 1977-01-11 Abbott Laboratories Treatment of specified neoplasias
US4071622A (en) 1976-02-11 1978-01-31 Abbott Laboratories Treatment of a mammary or DMBA inducible tumor
US4285930A (en) * 1977-12-08 1981-08-25 Likhite Vilas V Antigens comprising immunostimulant adjuvants and their use in immunotherapy
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4410510A (en) * 1980-03-10 1983-10-18 Virginia Livingston-Wheeler Method for preparing a purified extraction residue fraction and its use in stimulating the immune response
US4311688A (en) * 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
FR2475900A1 (fr) * 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
US4321260A (en) 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia
JPS5946487A (ja) 1982-09-10 1984-03-15 Hitachi Ltd 加熱装置
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms

Also Published As

Publication number Publication date
JPH07112981B2 (ja) 1995-12-06
JPS63501872A (ja) 1988-07-28
EP0249629A1 (de) 1987-12-23
WO1987003487A1 (en) 1987-06-18
US4689222A (en) 1987-08-25
EP0249629B1 (de) 1994-05-25
EP0249629A4 (de) 1989-11-09

Similar Documents

Publication Publication Date Title
ATE106016T1 (de) Verfahren und mittel zur erleichterung der schmerzen maligner tumore.
MY122383A (en) Cyclic boroproline compounds
EP0283713A3 (en) Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
DE3787403D1 (de) Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore.
AU7813191A (en) Novel immunoconjugates and methods for their use in tumor therapy
NO890089D0 (no) Fremgangsmaater for stimulering av haarvekst.
DE3679708D1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
EP0327640A4 (de) Immunotherapeutisches zubereitungen für die behandlung von aids.
ES8708183A1 (es) Un procedimiento para la preparacion de una composicion liofilizada de lipidos.
EP0199141A3 (de) Monoklonale Antikörper gegen humanen Magen-Darmkrebs
ATE40647T1 (de) Extraktionsverfahren von propolis, danach erhaltenes wasserloesliches getrocknetes pulver aus propolis, propolisenthaltende kosmetische und pharmazeutische praeparate.
OA07412A (fr) Benzoazacycloalhyl-spiro-imidazolidines leur préparation et leur application en thérapeutique.
ATE205394T1 (de) Lektinkonzentrate aus mistelextrakten und entsprechende standardisierte, stabilisierte mistellektinpräparate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel und deren verwendung zur erhöhung der natürlichen immunresistenz und/oder in der tumor-therapie
RU94022481A (ru) Способ определения иммуногенной активности биоактивных соединений и состав для его осуществления
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE3268159D1 (en) Medicaments based on algae, and formulations thereof
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
DE3781116D1 (de) Wirkstoffe zur verhuetung von tumormetastasen.
ATE109004T1 (de) Toleranzinduktion gegenüber einem fremdantigen.
EP0301373A3 (en) Products containing gallopamil and prazosine
DE69129232D1 (de) Zusammensetzung aus asphodelus zur erhöhung der anzahl weisser blutzellen
ES8300475A1 (es) Un procedimiento para la preparacion de un alergeno
EP0205293A3 (de) Verfahren zur Herstellung von Antikörpern
ATE66150T1 (de) Pharmazeutische zubereitung fuer orale verabreichung von eisensalzen, verwendbar zur behandlung von anaemien durch eisenmangel.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee